Clovis? IPO plan creates biotech buzz

Clovis Oncology Inc.’s Patrick Mahaffy is the man to watch in the coming months.

He has created a buzz second to none in the biotech world about whether his new cancer drug company Clovis Oncology in Boulder really will be able to raise $149.5 million in an initial public offering as suggested in the company’s recent registration filing with the U.S. Securities and Exchange Commission.

No date has been announced yet for the IPO.

It’s a huge no-no with SEC folks for a company to talk about a pending IPO, so Mahaffy and others at Clovis aren’t offering public comments. On the filing…